治疗前CT的定量影像特征可预测结直肠癌肝转移患者对化疗的容积反应
本研究纳入157例接受化疗的结直肠癌肝转移患者,从治疗前CT提取原发肝肿瘤的定量影像特征,构建线性回归模型预测肿瘤体积变化百分比。模型在训练集和验证集的平均绝对预测误差分别为16.5%和21.5%,提示定量影像特征有望预测化疗的容积反应。
要点
- 治疗前CT的定量影像特征(异质性和强化模式)可用于预测结直肠癌肝转移化疗后的体积变化。
- 多变量线性回归模型的平均绝对预测误差在训练集为16.5%(R2=0.774),验证集为21.5%。
- 按是否使用肝动脉灌注化疗分层,验证集误差在肝动脉灌注化疗组为19.6%,单纯全身化疗组为25.1%。
核心结论
- 从治疗前CT提取的定量影像特征有望预测结直肠癌肝转移患者对化疗的容积反应,治疗前反应预测因素可能有助于更好地为特定治疗选择患者。
研究设计与样本
- 研究类型为预测模型构建与验证研究,纳入接受化疗(肝动脉灌注化疗联合全身化疗或单纯全身化疗)的结直肠癌肝转移患者157例,分为训练集110例和验证集47例。
- 患者在基线和治疗后约8周接受影像检查,反应以肿瘤体积相对基线的百分比变化衡量。
- 定量影像特征取自治疗前CT上的指标肝肿瘤,单变量分析中显著的特征纳入线性回归模型预测容积反应,模型由70%数据构建,30%数据用于测试。
- 模型性能以平均绝对预测误差(MAPE)和R2评价。
关键影像表现/征象
- 结直肠癌肝转移的异质性和强化模式可通过定量影像测量。
诊断标准与关键数值
- 多变量线性回归模型在训练集的平均绝对预测误差为16.5%(R2=0.774),在验证集为21.5%。
- 按肝动脉灌注化疗使用情况分层,验证集平均绝对预测误差在肝动脉灌注化疗组为19.6%,在单纯全身化疗组为25.1%。
临床应用与阅片要点
- 治疗前CT的定量影像特征分析可用于预测结直肠癌肝转移化疗后的容积反应。
- 与中位肿瘤反应差异相关的临床因素包括治疗策略、全身化疗方案、年龄和KRAS突变状态(p < 0.05)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: This study investigates whether quantitative image analysis of pretreatment CT scans can predict volumetric response to chemotherapy for patients with colorectal liver metastases (CRLM).
METHODS: Patients treated with chemotherapy for CRLM (hepatic artery infusion (HAI) combined with systemic or systemic alone) were included in the study. Patients were imaged at baseline and approximately 8 weeks after treatment. Response was measured as the percentage change in tumour volume from baseline. Quantitative imaging features were derived from the index hepatic tumour on pretreatment CT, and features statistically significant on univariate analysis were included in a linear regression model to predict volumetric response. The regression model was constructed from 70% of data, while 30% were reserved for testing. Test data were input into the trained model. Model performance was evaluated with mean absolute prediction error (MAPE) and R2. Clinicopatholologic factors were assessed for correlation with response.
RESULTS: 157 patients were included, split into training (n = 110) and validation (n = 47) sets. MAPE from the multivariate linear regression model was 16.5% (R2 = 0.774) and 21.5% in the training and validation sets, respectively. Stratified by HAI utilisation, MAPE in the validation set was 19.6% for HAI and 25.1% for systemic chemotherapy alone. Clinical factors associated with differences in median tumour response were treatment strategy, systemic chemotherapy regimen, age and KRAS mutation status (p < 0.05).
CONCLUSION: Quantitative imaging features extracted from pretreatment CT are promising predictors of volumetric response to chemotherapy in patients with CRLM. Pretreatment predictors of response have the potential to better select patients for specific therapies.
KEY POINTS: • Colorectal liver metastases (CRLM) are downsized with chemotherapy but predicting the patients that will respond to chemotherapy is currently not possible. • Heterogeneity and enhancement patterns of CRLM can be measured with quantitative imaging. • Prediction model constructed that predicts volumetric response with 20% error suggesting that quantitative imaging holds promise to better select patients for specific treatments.
引用
- Creasy JM, Midya A, Chakraborty J, et al. Quantitative imaging features of pretreatment CT predict volumetric response to chemotherapy in patients with colorectal liver metastases. Eur Radiol. 2018. PMID: 29922934. doi:10.1007/s00330-018-5542-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。